Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?
暂无分享,去创建一个
M. Metra | G. Rosano | C. Maack | P. Ameri | J. Teerlink | Edoardo Bertero | E. Bertero
[1] Deepak L. Bhatt,et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.
[2] P. Ponikowski,et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. , 2020, The New England journal of medicine.
[3] P. Ponikowski,et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.
[4] P. Ponikowski,et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status , 2020, Circulation.
[5] P. Ponikowski,et al. Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure , 2020, European journal of heart failure.
[6] G. Filippatos,et al. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function , 2020, Circulation.
[7] P. Ponikowski,et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. , 2020, JACC. Heart failure.
[8] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[9] G. Filippatos,et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.
[10] D. DeMets,et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) , 2020, European heart journal.
[11] J. Rouleau,et al. Care Gaps in Adherence to Heart Failure Guidelines: Clinical Inertia or Physiological Limitations? , 2020, JACC. Heart failure.
[12] J. Januzzi,et al. Heart Failure With Reduced Ejection Fraction: A Review. , 2020, JAMA.
[13] B. Williams,et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure , 2020, European journal of heart failure.
[14] S. Solomon,et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.
[15] P. Ponikowski,et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.
[16] Akshay S. Desai,et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. , 2020, JAMA.
[17] G. Filippatos,et al. Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world , 2019, European journal of heart failure.
[18] G. Filippatos,et al. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial , 2019, European journal of heart failure.
[19] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[20] N. Jones,et al. Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis , 2019, European journal of heart failure.
[21] P. Ponikowski,et al. Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry , 2019, European journal of heart failure.
[22] Akshay S. Desai,et al. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) , 2019, European journal of heart failure.
[23] F. Viazzi,et al. Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure , 2019, Internal and Emergency Medicine.
[24] Declare–Timi Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .
[25] A. Hoes,et al. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry. , 2019, JACC. Heart failure.
[26] S. Hohnloser,et al. Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. , 2019, The American journal of cardiology.
[27] G. Filippatos,et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology , 2018, European heart journal.
[28] K. Swedberg,et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta‐analysis , 2018, European journal of heart failure.
[29] P. Ponikowski,et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study , 2017, European heart journal.
[30] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[31] J. Kautzner,et al. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis , 2017, European journal of heart failure.
[32] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[33] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[34] G. Bakris,et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors , 2015, European journal of heart failure.
[35] Akshay S. Desai,et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. , 2015, European heart journal.
[36] Christopher J. Rush,et al. Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. , 2015, JACC. Heart failure.
[37] P. Ponikowski,et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial , 2015, European journal of heart failure.
[38] G. Bakris,et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. , 2015, The New England journal of medicine.
[39] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.
[40] P. Ponikowski,et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† , 2014, European heart journal.
[41] P. Lavin,et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. , 2014, JAMA.
[42] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[43] P. Ponikowski,et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.
[44] D. Loo,et al. Biology of human sodium glucose transporters. , 2011, Physiological reviews.
[45] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[46] P. Ponikowski,et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. , 2010, European heart journal.
[47] K. Dickstein,et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial , 2009, The Lancet.
[48] Ralph D'Agostino,et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.
[49] P. Hinton,et al. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. , 2004, The American journal of clinical nutrition.
[50] P A Poole-Wilson,et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.